The UK's medicines regulator has officially endorsed microbiome-based medicinal products (MBMPs) as a legitimate class of therapeutics, paving the way for drugs that harness live bacteria and microbial communities to treat disease. While no such products have yet received UK approval, the Medicines and Healthcare products Regulatory Agency (MHRA) has published a position paper outlining how developers can bring these treatments to market, signaling a major shift in how the medical establishment views gut bacteria as medicine.

What Are Microbiome-Based Medicinal Products?

Microbiome-based medicinal products are a new class of drugs designed to prevent, treat, or diagnose disease by modifying or restoring the human microbiome. Unlike traditional probiotics or dietary supplements, these products contain live microorganisms, defined consortia of bacteria, or non-viable microbial components that are regulated as actual medicines. They can be administered orally, rectally, or vaginally, depending on the treatment target.

The distinction matters because it means these products must meet the same rigorous safety and efficacy standards as conventional drugs. The MHRA clarified that products marketed as foods, food supplements, cosmetics, or non-therapeutic probiotics fall outside this regulatory framework and remain unregulated.

Why Is the UK Taking This Step Now?

Microbiome research has revealed that the trillions of bacteria living in our gut influence everything from immune function to mental health to cancer risk. The potential to treat disease by modifying these microbial communities represents what the MHRA calls "an emerging class of therapeutics with the potential to address areas of significant unmet clinical need." In other words, there are diseases and conditions that current medicines cannot adequately treat, and microbiome interventions may fill that gap.

The regulatory endorsement comes as the US has already licensed two donor-derived microbiota products, putting the UK at risk of falling behind in this rapidly advancing field. By establishing clear pathways for approval, the MHRA aims to encourage UK-based developers to invest in microbiome drug development.

What Microbiome Treatments Already Exist?

One microbiome intervention is already in use in the UK: faecal microbiota transplantation (FMT), commonly known as a fecal transplant. This procedure involves transferring stool from a healthy donor to a patient's gut to restore beneficial bacteria. Currently, FMT is available in the UK primarily for recurrent Clostridioides difficile infections, a serious bacterial infection that causes severe diarrhea and can be life-threatening.

FMT is supplied through three routes: within clinical trials, as an unlicensed medicine under MHRA manufacturer's special licenses, or as an extemporaneously prepared medicine in a pharmacy. However, because these products are unlicensed, their quality, safety, and efficacy have not been formally assessed by the MHRA. The responsibility for safety falls directly on the prescribing doctor.

What Challenges Must Microbiome Drug Developers Overcome?

The biggest hurdle in developing microbiome medicines is inherent biological variability. Unlike traditional chemical drugs, which have a fixed composition, microbiome products can vary significantly from batch to batch. Some products contain multiple bacterial strains, others depend on donor material, and the composition can change during manufacturing and storage. Developers must establish robust strategies for identifying bacterial strains, assessing potency, controlling batch-to-batch consistency, and ensuring the product remains stable on the shelf.

Safety assessment requires particular attention to several critical concerns:

• Pathogenic Contamination: Ensuring the product does not contain harmful microorganisms or toxins that could sicken patients.
• Infection Risk in Vulnerable Populations: Assessing whether immunocompromised patients or those with severe illness could be harmed by live bacteria.
• Antimicrobial Resistance Transfer: Preventing the horizontal transfer of antibiotic-resistance genes from the product to a patient's own bacteria, which could render antibiotics ineffective.

The MHRA acknowledges that conventional toxicology studies, which work well for chemical drugs, may not reliably predict how microbiome products will behave in humans. Animal studies also have limited relevance because different species have fundamentally different microbiomes. As a result, the agency supports scientifically justified alternative approaches tailored to each product.

How Can Developers Get a Microbiome Drug Approved?

The MHRA has outlined a clear regulatory pathway for microbiome medicines. Developers must demonstrate appropriate standards of quality, safety, and efficacy using the existing UK medicines regulatory framework. Products may be regulated as biological medicinal products, since they are derived from living sources, or in some cases as advanced therapy medicinal products if they meet specific legal criteria.

A central requirement is thorough characterization of the product. Developers must identify Critical Quality Attributes, which are the molecular and biological characteristics necessary to ensure the product's consistency, safety, and efficacy. This includes defining the manufacturing process, establishing a control strategy to monitor batch quality, and demonstrating that the product remains stable throughout its shelf life. Current analytical tools are advancing rapidly, but developers must demonstrate that whatever tools they use are suitable for their intended purpose.

Steps for Microbiome Drug Development

While the MHRA's position paper is directed at pharmaceutical developers rather than patients, it outlines the scientific and regulatory framework that will govern how microbiome medicines reach the market. Here are the key steps developers must take:

• Strain Identification and Characterization: Precisely identify and document every bacterial strain in the product, including genetic markers and functional properties.
• Potency and Stability Testing: Demonstrate that the product maintains its therapeutic activity throughout manufacturing, storage, and shelf life, with robust controls to prevent batch-to-batch variation.
• Safety and Contamination Screening: Conduct comprehensive testing for pathogenic microorganisms, toxins, and antimicrobial resistance genes before the product reaches patients.
• Clinical Evidence Generation: Conduct human studies to prove the product is safe and effective for its intended indication, with particular attention to vulnerable populations.

What Does This Mean for Patients?

The MHRA's position paper does not immediately make new microbiome drugs available to patients. As of July 2026, no microbiome-based medicinal product has been granted UK marketing authorization. However, the regulatory framework now exists, and developers can begin submitting applications. Once approved, these products would undergo the same rigorous oversight as any other medicine, meaning patients could have confidence in their safety and efficacy.

For patients currently suffering from conditions that might benefit from microbiome interventions, clinical trials may offer access to experimental treatments. The MHRA encourages developers to pursue marketing authorization applications, suggesting that the agency is committed to moving these products through the approval process efficiently.

The shift toward regulating microbiome medicines as drugs rather than supplements or foods represents a fundamental change in how the medical establishment views the therapeutic potential of gut bacteria. As research continues to reveal the microbiome's role in disease, this regulatory framework will likely become increasingly important in bringing safe, effective microbiome-based treatments to patients who need them.